Taipei, Monday, April 21, 2014 06:14 (GMT+8)
mostly cloudy
Taipei
21°C
Apex to see sales grow 5-15% in 2013 - related company info
Ingrid Lee, Taipei; Steve Shen, DIGITIMES [Monday 21 January 2013]
  • Apex Biotechnology
  • Performance
    The company's stock price closed at NT$67.7 on the TSE on Thursday, April 17, 2014.
    The company has reported consolidated revenues of NT$138 million for March 2014, representing a 9.7% increase on month and 25.6% drop on year.
    For the fourth quarter of 2013, the company totaled NT$354 million in consolidated revenues, down 22% sequentially and down 26.5% on year.
    Brief

    Full name: Apex Biotechnology

    Chinese name: 五鼎生物技術股份有限公司

    Short name: Apex

    Stock code: 1733

    Tax ID: 16130182

    Market: TSE

    Established: 2 Dec 1997

    Paid in capital: NT$985.31 million

    Listed on TSE: 17 Sep 2001

    Website: www.apexbio.com

  • Latest stock
    Apex [1733] historical stock price (NT$)
    DateVolume (k)TransactionsValueOpenHighLowCloseChangeAskBid
    18-Apr 148 98 10,031,508 67.80 68.00 67.50 67.60-0.10-0.15% 67.70 67.60
    17-Apr 123 97 8,323,272 67.80 68.20 67.60 67.70-0.10-0.15% 67.80 67.70
    16-Apr 122 109 8,220,965 67.30 67.80 67.20 67.80+0.50+0.74% 67.80 67.50
    15-Apr 59 66 3,988,549 67.10 67.50 67.10 67.30+0.30+0.45% 67.30 67.20
    14-Apr 180 144 12,065,872 67.30 67.40 66.80 67.00-0.30-0.45% 67.10 67.00
    • Source: TSE, compiled by Digitimes
    Latest sales

    Apex: Consolidated revenues, Mar 2013 - Mar 2014 (NT$m)

    Month

    Sales

    M/M

    Y/Y

    YTD

    Y/Y

    Mar-14

    138

    9.7%

    (25.6%)

    423

    (19.2%)

    Feb-14

    126

    (20.7%)

    (20.4%)

    285

    (15.7%)

    Jan-14

    159

    26.5%

    (11.6%)

    159

    (11.6%)

    Dec-13

    126

    9.8%

    (20.5%)

    1,829

    (9.7%)

    Nov-13

    114

    (0%)

    (27.8%)

    1,704

    (8.8%)

    Oct-13

    114

    (25.9%)

    (30.9%)

    1,589

    (7%)

    Sep-13

    154

    0.3%

    8.4%

    1,475

    (4.5%)

    Aug-13

    154

    5.6%

    0.2%

    1,320

    (5.8%)

    Jul-13

    146

    3%

    (8.8%)

    1,166

    (6.5%)

    Jun-13

    142

    (17.9%)

    (14.3%)

    1,021

    (6.2%)

    May-13

    173

    (5.3%)

    (6.4%)

    879

    (4.8%)

    Apr-13

    182

    (2%)

    (9.5%)

    706

    (4.4%)

    Mar-13

    186

    17.4%

    (8.8%)

    524

    (2.4%)

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, April 2014

    Apex: Consolidated revenues, 4Q12 - 4Q13 (NT$m)

    Quarter

    Sales

    Q/Q

    Y/Y

    YTD

    Y/Y

    4Q-13

    354

    (22%)

    (26.5%)

    1,829

    (9.7%)

    3Q-13

    454

    (8.5%)

    (0.4%)

    1,475

    (4.5%)

    2Q-13

    497

    (5.2%)

    (9.9%)

    1,021

    (6.2%)

    1Q-13

    524

    8.7%

    (2.4%)

    524

    (2.4%)

    4Q-12

    482

    5.7%

    (3.1%)

    2,026

    8%

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, April 2014

    Latest balance sheet and income statement

    Apex: Consolidated balance sheet, 4Q12 - 4Q13 (NT$k)

    Item

    4Q-2013

    3Q-2013

    2Q-2013

    1Q-2013

    4Q-2012

    Current assets

    1,447,851

    1,347,766

    1,644,885

    1,922,635

    1,815,585

    Intangible assets

    26,174

    17,236

    17,816

    14,190

    14,554

    Non-current assets

    1,276,137

    1,341,620

    1,027,811

    967,210

    929,767

    Assets

    2,723,988

    2,689,386

    2,672,696

    2,889,845

    2,745,352

    Current liabilities

    383,354

    382,837

    416,522

    353,703

    336,313

    Non-current liabilities

    420,118

    421,334

    421,188

    419,978

    419,273

    Liabilities

    803,472

    804,171

    837,710

    773,681

    755,586

    Stockholders' equity

    1,920,516

    1,885,215

    1,834,986

    2,116,164

    1,989,766

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, April 2014

    Apex: Consolidated income statement, 4Q12 - 4Q13 (NT$k)

    Item

    4Q-2013

    3Q-2013

    2Q-2013

    1Q-2013

    4Q-2012

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    NT$k

    % of sales

    Gross sales

     

     

     

     

     

     

     

     

    486,607

     

    Operating revenue

    354,410

    72.8%

    454,277

    93.4%

    496,560

    102%

    523,974

    107.7%

    481,967

    99%

    Gross profit (loss) from operations

    106,527

    21.9%

    120,929

    24.9%

    169,175

    34.8%

    171,812

    35.3%

    190,327

    39.1%

    Operating expenses

    59,426

    12.2%

    51,361

    10.6%

    56,054

    11.5%

    52,611

    10.8%

    52,896

    10.9%

    Operating income (loss)

    48,747

    10%

    67,922

    14%

    113,121

    23.2%

    119,201

    24.5%

    137,431

    28.2%

    Non-operating revenues and gains

     

     

     

     

     

     

    25,800

    5.3%

    1,866

    0.4%

    Non-operating expenses and losses

    -3,812

    -0.8%

    -8,211

    -1.7%

    0

    0%

     

     

    -6,023

    -1.2%

    Income from continuing operations before income tax

    44,935

    9.2%

    59,711

    12.3%

    176,732

    36.3%

    145,001

    29.8%

    131,412

    27%

    Net income (loss)

    30,322

    6.2%

    51,591

    10.6%

    163,005

    33.5%

    125,925

    25.9%

    125,637

    25.8%

    Diluted earnings per share (NT$)

    0.1

     

    0.5

     

    1.6

     

    1.2

     

    1.2

     

    *Figures are consolidated
    Source: TSE, compiled by Digitimes, April 2014

  • Apex Biotechnology full profile

18-Apr-2014 markets closed

 LastChange

TAIEX (TSE)8966.66+22.50+0.25% 

TSE electronic342.87+1.95+0.57% 

GTSM (OTC)145.35+0.26+0.18% 

OTC electronic180.97+0.93+0.52% 

MSI product press release
DIGITIMES Marketing Services
2014 global smartphone market forecast